Cell phenotype as a target of drug therapy in chronic inflammatory diseases.

Cell phenotype as a target of drug therapy in chronic inflammatory diseases. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cell phenotype as a target of drug therapy in chronic inflammatory diseases. Abstract Text:

Many diseases share common pathological changes which could in principle be targets for new drugs. Vascular leakage of plasma and migration of cells into perivascular tissues are common to chronic inflammatory diseases such as asthma, atherosclerosis, arthritis, and proliferative nephropathy as well as some non-inflammatory proliferative disorders such as diabetes mellitus. Individual components of plasma have been shown to stimulate cellular proliferation, matrix deposition and phenotypic change, leading to tissue-damaging structural changes. Whereas most anti-inflammatory drugs either downregulate expression of inflammatory mediators or inhibit their actions on cells, there are alternate potential therapeutic strategies described here based on moderating vascular leakage or its consequences in chronic diseases. The hypothesis is that drugs that can modify a cell's phenotype could be used to limit structural changes which accompany inflammation and thus reduce permanent debility resulting from these diseases. Such drugs include the differentiating agents being developed for cancer therapy.

Cell phenotype as a target of drug therapy in chronic inflammatory diseases. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Cell phenotype as a target of drug therapy in chronic inflammatory diseases. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Medical hypotheses

VOLUME: 54

Page Numbers: 193-7

Journal Abbreviation: Med. Hypotheses

ISSN: 0306-9877

DAY: 15

MONTH: Feb

YEAR: 2000

Cell phenotype as a target of drug therapy in chronic inflammatory diseases. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7505668

Cell phenotype as a target of drug therapy in chronic inflammatory diseases. Keywords Mesh Terms:

KEYWORDS: Models, Biological

MESH TERMS: physiopathology

Chemical & Substance for Abstract: Cell phenotype as a target of drug therapy in chronic inflammatory diseases. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Cell phenotype as a target of drug therapy in chronic inflammatory diseases.

AFFILIATION: Department of Physiology and Pharmacology, University of Queensland, Brisbane, Queensland, Australia. shiels@plpk.uq.edu.au

Country: SCOTLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Med Hypotheses

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cell phenotype as a target of drug therapy in chronic inflammatory diseases Related Publications

• A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation.
• A refined agonist pharmacophore for protease activated receptor 2.
• Amyloid peptides and proteins in review.
• Cell phenotype as a target of drug therapy in chronic inflammatory diseases.
• Chronic gastritis as a source of gross hemorrhage; a report and discussion of four cases.
• Conformationally homogeneous cyclic tetrapeptides: useful new three-dimensional scaffolds.
• Consecutive cyclic pentapeptide modules form short alpha-helices that are very stable to water and denaturants.
• Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family.
• Current status of short synthetic peptides as vaccines.
• Cyclooligomerization of a helix-bearing template into macrocycles bearing multiple helices.
• EGL-1 BH3 mutants reveal the importance of protein levels and target affinity for cell-killing potency.
• Function, structure and therapeutic potential of complement C5a receptors.
• Hepta and octapeptide agonists of protease-activated receptor 2.
• Linkage Isomerism in the Binding of Pentapeptide Ac-His(Ala)3His-NH2 to (Ethylenediamine)Palladium(II): Effect of the Binding Mode on Peptide Conformation.
• New cysteine derivatives with antiproliferative activity on melanoma cells.
• New evidence of childhood leukaemias near nuclear power stations.
• Potent antimalarial activity of histone deacetylase inhibitor analogues.
• Profiling the enzymatic properties and inhibition of human complement factor B.
• Protease inhibitors in the clinic.
• Unexpected photolytic decomposition of alkyl azides under mild conditions.